Research Involving Controlled Substances - Quick Guide to Getting Started The Office of Research Compliance v. Jan 2013.

Slides:



Advertisements
Similar presentations
Common/shared responsibilities between jobs.
Advertisements

Tips to a Successful Monitoring Visit
Introduction to Records Management Policy
HIPAA Privacy Training. 2 HIPAA Background Health Insurance Portability and Accountability Act of 1996 Copyright 2010 MHM Resources LLC.
“Medication Units” (Opioid Treatment Programs) Drug Enforcement Administration James “Jim” Arnold Chief, Policy Unit Office of Diversion Control D E A.
SOP Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Santiago, Chile August.
Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Board Meeting April 8, 2015.
Drug Enforcement Administration Diversion Investigator Angela Lee.
Confidential 1 Electronic Prescribing of Controlled Substances (EPCS) Part 1 of a 3 Part Series Chuck Klein, Ph.D. GM/Director, Medication Management.
Controlled Substances in the Institutional Setting NYS Council of Health-system Pharmacists May 3, 2009 Victoria A. Hanson, R.Ph., B.S. Pharmacy Consultant.
U.S. Department of Justice Drug Enforcement Administration Office of Diversion Control Electronic Prescriptions for Controlled Substances Michelle Ferritto,
Recently Issued OHRP Documents: Guidance on Subject Withdrawal and Draft Revised FWA Secretary’s Advisory Committee on Human Research Protections October.
Form I-9 Process An Online Training for Supervisors and Designees Presented by Human Resources Revised November 2009.
Developing a Records & Information Retention & Disposition Program:
Controlled Substance Training Environmental Health & Safety Deona Willes, Deputy Director, EHS Dan Shapiro, Director, Office of Compliance Vivek Dharne,
CUMC IRB Investigator Meeting Human Subjects Research Non-Compliance September 15, 2005.
INTERNAL CONTROLS. Session Objectives Understand why an organization should have internal controls Understand the key components of internal controls.
Secure and Responsible Drug Disposal Act of 2010 Takes Effect 10/9/2014 DEA’s goal in implementing the Act is to expand the options available to safely.
Controlling Controlled Substances Russell Griffin McKinney Fire / EMS EMS Coordinator.
Investigational Pharmacy Issues Debbie Mundie, RPH Aka: The Drug “Nazi” “She should be in Law Enforcement” “She’s nice, but PICKY” McGuire VAMC Richmond.
Institutional Review Board (IRB) Human Subject Research Office (HSRO) University of Miami and Affiliated Institutions.
Coordinator University Clinical Research Pharmacy Investigational Drug Service (IDS) Marjorie Shaw Phillips, MS, RPh, FASHP Clinical Research Pharmacist.
FDA shall issue a certification for those FDA licensed establishments applying for amendment during the validity of their Licenses to Operate. This certification.
Federalwide Assurance Presentation for IRB Members.
U.S. Department of Justice Drug Enforcement Administration Office of Diversion Control Electronic Prescriptions for Controlled Substances June 1, 2010.
California State Board of Pharmacy Continuing Education Program Senate Bill 151 (Burton)
Richard Z Aramini, PharmD PGY-1 Pharmacy Practice Resident Bay Pines VA Healthcare Center.
Research and Development Protocol Submission and Continuing Review Processes Kimberly Summers, PharmD Assistant Chief for Clinical Research South Texas.
P R E S E N T E D B Y: Carol Goularte Pharmacy Buyer Sierra Nevada Memorial Hospital August 19, 2009 Pharmaceutical Recall Process.
Chapter 1. OBJECTIVES  see p-2 of text book KEY TERMS / CONCEPTS  controlled substances  Drug Enforcement Administration (DEA)  drug standards  Food.
1 Records Inventory & Data Classification Workshop Data Classification Project Note: This is an example of one agency’s approach to meeting the state records.
Drug Abuse … the prevalence of severe drug abuse problems and their consequences has increased since 1985…. The Economic Costs of Alcohol and Drug Abuse.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
ZHRC/HTI Financial Management Training Session 9: Stores and Supplies Management.
1 January 17, 2008 Test Article Accountability. 2 January 17, 2008 Investigator Responsibilities 21 CFR  Maintain control of drug under investigation.
Tajikistan Making Opioids Available in Eastern Europe and Central Asia March 5-6, 2013 Vienna.
An introduction to records management at Clemson University Records Management Office 139 Anderson Hwy, Suite 100 Clemson, S.C
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
Ensuring Availability and Preventing Diversion International Pain Policy Fellowship August 7, 2012 David E. Joranson University of Wisconsin Pain & Policy.
Drug Regulations & Control
LECTURE FOR ASSIGNMENT 1 AND 2
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
Copyright © 2010 Delmar, Cengage Learning. ALL RIGHTS RESERVED. Chapter 35 Basic Pharmacology.
1 Privacy Plan of Action © HIPAA Pros 2002 All rights reserved.
Minnesota Department of Health Assisted Living Home Care Provider Licensing Surveys Surveys Conducted May – October 2005 © Care Providers of Minnesota.
Dean R Hatt. Famous Quotes  “Drug misuse is not a disease, it is a decision, like the decision to step out in front of a moving car. You would call.
Investigational Devices and Humanitarian Use Devices June 2007.
An introduction to records management at Clemson University Records Center is located at the Library Depot 103 Clemson Research Blvd Anderson, S.C
Authorization Part III. Content of a license Structure of a license General elements General and specific conditions Annexes Documents attached (e.g.
Paul Kelly Facility Research Compliance Officer for the Ralph H. Johnson VA Medical Center.
IP Accountability in Outpatient Clinical Trials
Table of Contents.  Legal and Safety Issues Go Go  Prescriptions and Abbreviations Go Go.
Storage, Labeling, Controlled Medications Guidance Training CFR § (b)(2)(3)(d)(e) F431.
Controlled Substances
IP Accountability in Outpatient Clinical Trials Jessica Rinaldi, CCRP Farber Institute for Neurosciences.
ABC-MAP Act 191 of 2014 September 16, 2016 Pennsylvania’s Prescription Drug Monitoring Program (PA PDMP)
Quick Regulatory Guide
FSEP Year End Reminders
Drugs and Prescription Records
Drugs and Prescription Records
Elements of an Organized Regulatory Binder
RECORDS AND INFORMATION
Investigator of Record – Definition
Controlled Substances
Chapter 35 Basic Pharmacology.
Controlled Substances
Compounded Drugs and Lack of Premarket FDA-Approval
Controlled Substances
INTRODUCTION: Medications not being given must be safely stored
OSU Controlled Substances Training Module for Researchers
Presentation transcript:

Research Involving Controlled Substances - Quick Guide to Getting Started The Office of Research Compliance v. Jan 2013

Introduction Animal, human or in vitro research involving the use and possession of controlled substances is highly regulated and requires central notification at our Health System as well as appropriate registration and licensing from state and federal agencies. It is important to be familiar with our institutional policies and process not only to ensure compliance with the various regulatory requirements, but to ensure that your study can be conducted smoothly and in a timely fashion.

Learning Objectives This presentation will cover basic information about this process to get you started and direct you to the appropriate contact depending on the type of research you plan to conduct. In general it will familiarize you with the following: 1)How to access our Health System’s Research Policy governing research using controlled substances 2)NY State license requirements and application form 3)Federal DEA registration requirements and application form 4)Other key requirements

Schedules of Controlled Substances There are 5 schedules: Schedule I: High potential for abuse with no currently accepted medical use in the U.S. (e.g. heroin, marijuana, LSD) Schedule II: High potential for abuse with severe psychic or physical dependence liability. (e.g. morphine, codeine, methadone, methylphenidate, amphetamine) Schedule III: Potential for abuse less than those in schedule I and II with compounds containing limited quantities of certain narcotic and non-narcotic drugs (e.g. ketamine) Schedule IV: Potential for abuse less than those in schedule III (e.g. phenobarbital, chloral hydrate, and diazepam (Valium)) Schedule V: Potential for abuse less than those in schedule IV and consist of preparations containing limited quantities of certain narcotic drugs. You can find drug schedules listed in NYS Article 33

What is our Health System Policy? You should familiarize yourself with our institutional policy, which you can access through HealthPort by:  Clicking on the Policies tab  Then click on the “Research Policies” tab under your site  Scroll down to the section: “Use of Drug and Investigational Products”  Then click on “GR050: Use of Controlled Substances in Research” Notification that controlled substances will be used in research is required, which you can do by submitting a notification form to:  For human research: (regardless of which IRB you  For animal research:  For in vitro research:

More about the Notification Form The notification form should be completed prior to initiating any research and making any changes to your research related to controlled substances being used or personnel handling the substances. Notification of the Office of Research Compliance that controlled substances will be used in research is also required, which you can do by scanning license and registrations to:  ORC Mailbox: or

What are NY State Requirements? Key things to know: Researchers require separate state licenses and DEA registrations to engage in research with controlled substances even if one already has a clinical or professional license Licenses are issued by the NYS Bureau of Narcotic Enforcement and must be renewed every two years The NYS license must be obtained before the DEA registration Outpatient prescriptions require use of official NYS prescription forms Mandatory reporting of dispensed controlled substances to NYS is required electronically every month

How Do I Apply for a NY State License? Step 1: Download the license application form (DOH 4330) and instructions online at: Step 2: Determine your license classification: Schedule I researchers should apply for a Class 7 individual license Schedule II-V researchers should apply for a Class 4 individual license Contact the Office of Research Compliance for institutional license matters for schedule II-V. Step 3: Read instructions for the following: Required information to be submitted with the application Minimum security requirements including safe specifications Note: Researchers conducting human subject research must submit IRB approval correspondence with the application

Where Can I Find More NYS Information? NYS Bureau of Narcotic Enforcement Web Site For further information, forms and guides for physicians and pharmacists: NYS Laws and Regulations Access Article 33 to look up schedules of drug and Title 10 Part 80 for regulations governing this activity: Please take the time to read the “Dear Researcher” letter from NYS: 01_controlled_substance_license.htm

What are Federal Requirements? Key Things to Know: Investigators must be registered as a DEA Researcher; researchers require annual renewal of registration Each separate site of activity must be DEA registered Federal registration does NOT overrule state restrictions Additional Requirements for Schedule I & II: Supply must be requested using DEA Form 222 Researchers conducting research with Schedule I substances must: –Hold a separate Federal Research DEA Registration –(For Clinical Investigations): Submit to FDA a “Notice of Claimed Investigational Exemption for New Drug (IND)” (from: –Submit proof of Institutional (and IRB for human studies) approval

How Do I Obtain a DEA Registration? You must register as a researcher by following the steps below: Step 1: Download the DEA application form 225 (or complete it online) and access instructions by going to: Step 2: Determine your business activity: Researcher with Schedule I OR Researcher with Schedule II-V Note that each activity requires a separate application You will need to include your NYS license number Step 3: See page 4 (or click on “Attachments”) for: Additional instructions Required attachments for Schedule I researchers

Where Can I Find DEA Information? DEA Web Site for Registration For further information, tools and resources: Federal Laws and Regulations The Controlled Substance Act, regulations, Q&A, and legal information: Section Pertaining to Research Protocols & Schedule I

How Do I Authorize Staff to Handle Controlled Substances? License/Registration holders must do the following: Limit access only to employees or agents under their supervision who require handling of controlled substances issued to them as part of the research. Formally authorize employees or agents by performing appropriate screening of each user and maintain a list of authorized users. – Use the Authorized User of Controlled Substances in Research Screening Form (available through HealthPort under Research Policies) – Work with HR to handle any issues related to screening and store forms in a secure location Note that any additional prescribers must obtain their own separate license/registration. License/Registration holders are ultimately responsible and accountable for adherence to policies and regulations including authorized personnel.

Storage and Security Requirements Key things to know: Supply should be stored in a locked, secure area with limited access and appropriate security measures to prevent theft or diversion There are minimum storage requirements for main and working stocks depending on the schedule of drug –(see specifications in the NYS application instructions) Applicants are subject to an on-site inspection by NYS Do not store drug in a locked box that can easily be lifted or an unlocked desk drawer.

Record Keeping Requirements Documentation must be maintained that clearly tracks the chain of custody of controlled substances from receipt to final disposition, and be made readily available upon inspection. The following must be maintained for at least 5 years: Applications, issued license/registration, authorized user screening, and any other relevant forms Purchase orders and forms Orders/prescriptions Records for receipt and use (including dispensing) Disposal, theft and loss records Inventory records (including required biennial inventory) Documentation must be attributable (e.g. identifies the individual recording the information and represents what actually occurred).

How Do I Dispose of Unused Drug? We recommend returning unused drug to the original distributor/manufacturer or disposing it off-site through an approved reverse distributor that is licensed/registered by the State and DEA. See approved Reverse Distributor list at: ender_to_independent_companies.htm ender_to_independent_companies.htm On-site destruction is not recommended and requires prior authorization by NYS. Please contact the appropriate office listed at the end of this presentation for assistance.

What Should I Do in the Case of Theft or Loss? This should be promptly reported to the Office of Research Compliance and Corporate Security for investigation and required actions. Formal reporting to NYS and the DEA may be required, and should be done in conjunction with the Office of Research Compliance. NYS Loss of Controlled Substances Report: DEA Theft or Loss of Controlled Substances: dex.htmlhttp:// dex.html The DEA requires reporting knowledge of drug diversion by employees or colleagues to the responsible security official

Helpful Tips Allow time to obtain proper licenses & registrations, particularly if separate approvals are required Have pharmacy store and dispense drug Check expirations dates of drug regularly Place a reminder in your calendar for license/registration renewals Provide education for all personnel involved in handling controlled substances Be prepared for routine or for case audits or investigations by documenting well and ensuring that records are organized

Research Administration P(516) or Office of Research Compliance P(516) or IACUC P(516) Contacts Us for Questions or Assistance Animal Research Human Research In Vitro Research